Integral Diagnostics (ASX:IDX): FY26 Financial Results and Medical Imaging Operations

Aditi Sarkar

26 October 2026 03:57 PM AEDT

Integral Diagnostics (ASX:IDX): FY26 Financial Results and Medical Imaging Operations

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Integral Diagnostics (ASX:IDX) reported FY26 revenue and other income of AUD 788.7mn, up 25.6% YoY.
Operating EBITDA increased 30.3% YoY to AUD 164.8mn, with a margin of 20.9%.
Operating NPAT rose 50.1% YoY to AUD 47.4mn; statutory NPAT reached AUD 22.0mn.
Net debt to operating EBITDA declined to 2.3 times at 30 June 2026.

Integral Diagnostics Limited provides diagnostic medical imaging services across Australia and New Zealand through a network of clinics and specialist imaging operations. Its latest FY26 results documented higher revenue, earnings and operating cash flow following the expansion of its network. During trading on 26 October 2026, Integral Diagnostics (ASX:IDX) was quoted at AUD 2.10, up 0.48% for the session. The company’s annual disclosures also outlined integration activities, operating efficiency measures and priorities for FY27.

Company Business

Integral Diagnostics (ASX:IDX) delivers radiology and diagnostic imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, X-ray and other specialist procedures. Its operations serve patients and referring clinicians in metropolitan and regional locations across Australia and New Zealand. The group operates through radiologist-led clinical services, imaging centres and supporting technology infrastructure.

The business combines patient-facing imaging sites with specialist reporting capability. Recruiting and retaining radiologists, managing equipment utilisation and maintaining access to clinical appointments are operational considerations. The integration of the acquired Capitol Health network has also influenced the scale and composition of the group’s reported results during FY26.

Recent Development

In August 2026, Integral Diagnostics (ASX:IDX) released its results for the year ended 30 June 2026. The report showed an improvement in operating margins and a reduction in the group’s net debt leverage measure. Management identified core growth and optimisation, selective network expansion, people and culture, and transformation and innovation as its four strategic priorities for FY27 and later periods.

The company outlined aims to improve productivity and patient access, expand imaging capacity where appropriate and support more efficient clinical workflows. Its 2026 annual general meeting was scheduled for 29 October 2026, providing a near-term corporate update point following the annual results. Future network decisions will depend on service demand, staffing, capital expenditure and integration execution.

Financial Performance and Sector Context

Integral Diagnostics (ASX:IDX) reported FY26 revenue and other income of AUD 788.7mn, an increase of 25.6% YoY. Operating EBITDA reached AUD 164.8mn, up 30.3% YoY, while the operating EBITDA margin improved to 20.9% from 20.1%. Operating NPAT increased 50.1% YoY to AUD 47.4mn. The statutory net profit after tax was AUD 22.0mn, incorporating AUD 25.4mn in specified transaction, integration, restructuring, contingent consideration and related share-based items after tax.

Operating free cash flow rose 30.7% YoY to AUD 106.4mn, and cash-flow conversion was 82.0%. The net debt-to-operating EBITDA ratio declined to 2.3 times from 2.6 times at the prior year-end. Operating diluted earnings per share increased 23.6% YoY to 12.6 Australian cents. These measures distinguish the group’s underlying operating performance from statutory results affected by integration-related expenditure.

Demand for diagnostic imaging is affected by patient referrals, healthcare funding arrangements, access to qualified clinicians and investment in equipment. The group identified improved productivity, capacity and patient access as operating priorities. Government policy relating to imaging services can also affect procedure volumes and funding economics.

Risks to Consider

Integral Diagnostics (ASX:IDX) faces workforce availability constraints, particularly in recruiting radiologists and specialist staff, as well as cost pressures associated with labour, technology and imaging equipment. Integration of acquired practices requires consistent systems, clinical processes and operational controls. Financing costs and leverage remain relevant despite the reduction in the group’s reported debt ratio. Changes in reimbursement settings or referral patterns could influence activity and margins.

What to Watch Next

The group’s stated FY27 focus includes sustainable revenue growth, an operating EBITDA margin above 21.0%, higher productivity and capacity, improved patient access and further debt reduction. Integral Diagnostics (ASX:IDX) expected FY27 replacement and growth capital expenditure of AUD 50.0mn to AUD 60.0mn. Subsequent announcements may show progress against these objectives, together with utilisation, workforce capacity, acquisition integration and cash generation.

Key Insights

Integral Diagnostics (ASX:IDX) ended FY26 with higher operating earnings, increased free cash flow and lower net debt leverage. The company’s FY27 priorities centre on organic optimisation, selective expansion, workforce capability and service delivery efficiency. The next reporting periods will show how these objectives translate into margins, capital spending and balance-sheet measures.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.